Skip to main content

Table 1 Baseline characteristics

From: Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

 

Implementation group (n = 119)

Control group (n = 93)

Total (n = 212)

Sex (male)—n (%)

63 (52.94)

51 (54.84)

114 (53.77)

Age (years)

 mean

72.14

69.65

71.21

 SD

10.67

14.23

12.20

Amiodarone—n (%)

3 (2.52)

4 (4.26)

7(3.30)

Alcohol intake (units per day)—n (%)

 < 1

62 (52.99)

62(66.67)

122(58.10)

 1–5

34(29.06)

21(22.34)

57(27.14)

 6–14

10(8.55)

7(7.45)

19(9.05)

 15–21

9(7.69)

1(1.06)

10(4.76)

 22–49

2(1.71)

2(2.13)

4(1.90)

 missing

2

 

2

Smoking status—n (%)

 Current

19(16.10)

14(14.89)

33(15.64)

 Previous

39(33.05)

37(39.78)

76(36.02)

 Never

60(50.85)

42(44.68)

102(48.34)

 Missing

1

 

1

Indication—n (%)

 AF

111 (93.28)

56(59.57)

167(78.77)

 DVT

4(3.36)

17(18.09)

21(9.91)

 PE

4(3.36)

20(21.51)

24(11.32)

CYP2C9*2—n (%)

 *1/*1

91 (76.47)

  

 *1/*2

27(22.69)

  

 *2/*2

1(0.84)

  

CYP2C9*3—n (%)

   

 *1/*1

105(88.24)

  

 *1/*3

14(11.76)

  

 *3/*3

0 (0.00)

  

VKORC1—n (%)

 G/G

49(41.18)

  

 G/A

57(47.90)

  

 A/A

13(10.92)

  

Target INR range—n (%)

 2–3

115(96.64)

92(98.93)

207(97.64)

 2–2.5

0(0.00)

1(1.06)

1(0.47)

 2.5–3.5

3(2.52)

0(0.00)

3(1.42)

 1.8–3.2

1(0.84)

0(0.00)

1(0.47)